Skip to Content
Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 02/06/19

Bladder SPOREs

Bladder cancer has an estimated 81,190 new cases and 17,240 deaths and has a higher incidence in men than in women. The percent of patients surviving for 5 years is 76.8%. The University of Texas/MD Anderson Bladder SPORE was initiated in 2001 with the goal of developing new cancer interventions through molecular-based translational research. The Memorial Sloan Kettering Cancer Center Bladder SPORE was recently funded in 2018 with goals to explore the molecular basis of inherited genetic susceptibility in bladder cancer, exploit prospective molecular characterization to guide treatment, and to test the efficacy of immunotherapy-based combination approaches to treat this disease.

Translational research projects in the bladder SPOREs include a genome analysis of microRNA in the risk and outcome of bladder cancer, targeting growth factor receptors, and enzymes involved in tumor cell growth, and identifying rational targets for effective combinatorial therapies. Other projects aim to explore immunologic predictors of BCG immunotherapy and gene therapy for BCG refractory bladder cancer as well as treatment options including checkpoint blockade immunotherapy and exploring why some patients become resistant to immunotherapy. All projects have a human endpoint and aim for translation of findings to the clinical setting.